Development Milestone Event Milestone Payment. 1 […***…] […***…] 2 […***…] […***…] 3 […***…] […***…] 4 […***…] […***…] 5 […***…] […***…] 6 […***…] […***…] 7 […***…] […***…] 8 […***…] […***…] Total […***…] † The specific required criteria known as “D4” are, as of the Effective Date, set forth in that certain email communication from Bayer to Dimension dated April 30, 2014. Each milestone payment is payable […***…], regardless of the number of times the corresponding event is achieved by a Licensed GT Product and/or Licensed Treatment and regardless of the number of Licensed GT Products and/or Licensed Treatments to achieve such event. Under no circumstances shall Bayer be obligated to pay Dimension more than […***…] pursuant to this Section 6.2. For the avoidance of doubt, the Parties acknowledge and agree that, (a) with respect to Milestone […***…] above, in the event that some but not all of the criteria for […***…] are met for a Licensed Product and/or Licensed Treatment, such that there is no current achievement of […***…] as defined, then to the extent the subsequent milestone event (i.e., Milestone […***…]) is achieved at a later date for such Licensed Product and/or Licensed Treatment, […***…] shall be deemed to have occurred at such later date and the corresponding milestone payments for both Milestone […***…] and Milestone […***…] shall be paid together; and (b) if the […***…], then all development milestone events relating to […***…] shall be deemed to have been met. To that end, if for any reason, any such related milestone payments have not been made, such milestone payments shall be due and owing upon […***…]. For example: if […***…] and any of Milestone Events […***…] or […***…] have not been paid for any reason, all such unpaid milestones shall be paid together with the payment of the milestone payment for the achievement of development Milestone Event […***…].
Development Milestone Event Milestone Payment. Upon [***]. ¥[***]
Development Milestone Event Milestone Payment. (i) Earlier of (a) the first Successful Completion of a Phase 1 Clinical Trial, following the ad hoc JSC meeting pursuant to Section 4.4(b) to evaluate the tabulated data from such trial or (b) Initiation of the first Phase 2 PoC Clinical Trial Four million Dollars ($4,000,000) [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] Total Either • Fifty million five hundred thousand Dollars ($50,500,000) (if milestone (iv) above is achieved on or before [**]) or • Forty-three million Dollars ($43,000,000) (if milestone (iv) above is achieved on or after [**]) Each milestone payment is payable one time only, regardless of the number of times the corresponding event is achieved by a Licensed Product and regardless of the number of Licensed Products to achieve such event. Under no circumstances shall Jazz be obligated to pay Concert more than fifty million five hundred thousand Dollars ($50,500,000) pursuant to this Section 6.3. If a milestone event set forth in (ii) through (v) of the table above is achieved prior to the achievement of an earlier milestone set forth in (i) through (iv) of the table above, or if a milestone event set forth in (vi) and (vii) of the table above is achieved prior to the achievement of an earlier milestone set forth in (i), (ii) or (vi) of the table above, then payment for such earlier unachieved milestone payment shall be due and payable simultaneously with the payment of the later milestone event.
Development Milestone Event Milestone Payment. Initiation of the first [*****] Clinical Trial [*****] Dollars ($[*****]) First Regulatory Approval in [*****] [*****] Dollars ($[*****]) First Regulatory Approval by [*****] [*****] Dollars ($[*****]) First Regulatory Approval in [*****] [*****] Dollars ($[*****]) Each milestone payment is payable one time only for each Exclusive Program, regardless of the number of times the corresponding event is achieved by an Exclusive Product in each Exclusive Program and regardless of the number of Exclusive Products in each Exclusive Program to achieve such event. Under no circumstances shall Ziopharm be obligated to pay Precigen more than fifty-two million five hundred thousand Dollars ($52,500,000) pursuant to this Section 6.2 for each Exclusive Program or more than [*****]Dollars ($[*****]) in total for all four Exclusive Programs under this Agreement.
Development Milestone Event Milestone Payment. [*****] [*****]
Development Milestone Event Milestone Payment. First IND Acceptance for a Licensed Product [***] Initiation of the first Phase 2 Clinical Trial of a Licensed Product [***] Initiation of the first Pivotal Clinical Trial of a Licensed Product [***] First Regulatory Approval of a Licensed Product in the U.S. for a first Indication [***] First Regulatory Approval of a Licensed Product in the U.S. for a second Indication [***] First Regulatory Approval of a Licensed Product in the U.S. for a third Indication [***] First approval of a BLA for a Licensed Product by the EMA [***] First approval of a BLA for a Licensed Product in Japan [***] Each milestone payment set forth above shall be payable only once, regardless of the number of times the applicable milestone event is achieved by any Licensed Product and regardless of the number of Licensed Products to achieve the applicable milestone event. Under no circumstances shall Kxxxxx be obligated to pay GigaGen more than twenty million Dollars ($20,000,000) under this Section 4.2.
Development Milestone Event Milestone Payment. [*] If Genentech ceases clinical development of a NLG919 Product after having made one or more payments due under this Section 7.3(a) upon the achievement of a particular milestone event by such NLG919 Product, then there shall be no payment due upon accomplishment of that same milestone with respect to any other NLG919 Product to achieve such milestone event. Confidential Execution Version
Development Milestone Event Milestone Payment. [*] In no event shall the cumulative total amounts payable under this Section 7.3(b) exceed [*] Dollars ($[*]) for a Next Generation Product that achieves all [*] milestones. Without limiting the foregoing, in no event shall the aggregate amount payable by Genentech under this Section 7.3(b) exceed [*] Dollars ($[*]).
Development Milestone Event Milestone Payment. [*] [*] In the event that a milestone payment with respect to milestone event [*] has not been paid at such time as milestone event [*] is achieved, then Mylan shall pay Revance such unpaid milestone payment with respect to milestone event [*] along with its payment for the first of such later milestone events ([*]) to occur. In the event that a milestone payment with respect to milestone event [*] has not been paid at such time as milestone event [*] is achieved, then Mylan shall pay Revance such unpaid milestone payment with respect to milestone event [*] along with its payment for milestone event [*]. In the event that a milestone payment with respect to milestone event [*] has not been paid at such time as a milestone event [*] is achieved, then Mylan shall pay Revance such unpaid milestone payment with respect to milestone event [*] along with its payment for milestone event [*].
Development Milestone Event Milestone Payment. [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] The provisions regarding milestone payments set forth in Section 6.3.4 shall be applicable to each [***] and to [***] individually. For clarity, a separate set of milestone payments will be payable for each of [***] and [***].
